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ABSTRACT:
Annexins are a structurally related family of calcium and phospholipid-binding 
proteins that are involved in the regulation of a wide range of molecular and 
cellular processes. Annexin A2 is unique among the annexins in that it possesses 
redox sensitive cysteine(s). The ubiquitous and abundant expression of ANXA2 
in cells and its reactivity with hydrogen peroxide led us to hypothesize that this 
protein could play a role in cellular redox regulation. Here we show that ANXA2 
protein levels are induced by hydrogen peroxide. Furthermore, depletion of ANXA2 
resulted in the elevation of cellular reactive oxygen species (ROS) upon oxidative 
stress, increased activation of the ROS-induced pro-apoptotic kinases, JNK, p38 
and Akt and elevated sensitivity to ROS-mediated cellular damage/death. ANXA2-
null mice showed significantly elevated protein oxidation in the liver and lung tissues 
compared to WT mice. ANXA2 depleted cancer cells showed enhanced cellular 
protein oxidationconcomitant with decreased tumor growth compared to control 
cancer cells andboth the oxidation of cellular proteins and tumor growth deficit 
werereversed by the antioxidant N-acetyl cysteine, indicating that ANXA2 plays akey 
role in the regulation of cellular redox during tumorigenesis. Ex-vivo human cancer 
studies showed that up-regulation of the reduced form of ANXA2 is associated with 
protection of the tumor proteins from oxidation. In summary, our results indicate 
that ANXA2 plays an important role incellular redox regulation by protecting cells 
from oxidative stress, aneffect that is particularly important during tumorigenesis.
INTRODUCTION
Reactive oxygen species (ROS) are oxygen-
containing reactive chemical species which include such 
biologically important molecules as superoxide, nitric 
oxide, hydroxyl radical and hydrogen peroxide (H2O2). 
Endogenous H2O2 is a by-product of mitochondrial 
respiration [1]. In addition, various signaling molecules, 
including growth factors, cytokines, hormones and 
neurotransmitters induce increases in intracellular H2O2 
through the activation of NADPH oxidases (Nox). H2O2-
dependent signaling has been implicated in diverse 
processes such as regulation of cell proliferation, 
differentiation, migration and apoptosis [2, 3, 4]. The 
production of a cytotoxic molecule has obvious potential 
risks to the cells as H2O2 is a major contributor to DNA 
damage, protein oxidation and lipid peroxidation [5, 6]. 
Cells therefore show a biphasic response to increased 
H2O2 levels; this is due to its role as a second messenger in 
intracellular signaling cascades (proliferative effect) and 
at high concentrations as an oxidant of proteins, lipids and 
nucleic acids (apoptotic and/or necrotic effect).
Cancer cells typically express higher levels of 
ROS  compared to normal cells which gives them 
both a proliferative advantage and also promotes 
malignant progression [7, 8]. Ionizing radiation (IR) 
and chemotherapeutic drugs that elevate ROS levels are 
toxic to cancer cells because the same dosage of drug or Oncotarget 2011; 2:  1075 - 1093 1076 www.impactjournals.com/oncotarget
radiation will cause death of the cancer cell due to ROS 
overload, but will be less toxic to neighboring normal 
cells which contain lower endogenous levels of ROS.
Redox-sensitive cysteines are the primary target for 
protein oxidation by H2O2. The amino acid cysteine can 
exist in proteins as a Cys sulfhydryl group (Cys-SH) or 
a Cys thiolate anion group (Cys-S-). Since the pKa value 
of most protein Cys residues is about 8.5, at neutral pH 
most Cys residues are in the Cys-SH form. However, a 
very small subset of proteins contain Cys residue(s) in the 
Cys-S- form at neutral pH typically due to the stabilization 
of this form by salt bridges to positively charged amino 
acids. Only the Cys-S- form is readily susceptible to 
oxidation by ROS and for this reason is referred to as a 
redox-sensitive cysteine. The redox-sensitive cysteines 
function as sensors of H2O2 and the oxidation of these 
residues affects the biological activity of the protein. 
For example, certain transcription factors such as JunD 
have a redox sensitive cysteine strategically positioned 
within their DNA binding domains such that oxidation 
of this cysteine by H2O2 blocks DNA-binding activity. 
Alternatively, antioxidant proteins utilize their redox 
sensitive cysteine(s) catalytically to reduce H2O2 to H2O.
Cells have developed several antioxidant systems 
to avoid ROS induced damage. These include catalase, 
superoxide dismutase, glutathione peroxidase and 
thioredoxin peroxidase (peroxiredoxins). The primary 
redox sensitive cysteine reductases are thioredoxin (Trx) 
and glutathione (GSH). Trx regulates signaling molecules, 
transcription factors, peroxidases and mediates redox-
regulated gene expression [9]. During reduction of target 
proteins, Trx is oxidized and subsequently reduced/
regenerated by thioredoxin reductase and NADPH. The 
Trx, Trx reductase and NADPH, collectively called the 
Trx redox system, constitute a fundamental antioxidant 
system. 
Annexins are a structurally related family of calcium 
and phospholipid-binding proteins that are involved in the 
regulation of a range of molecular and cellular processes 
[10, 11]. The de-regulated expression of annexins has 
been shown to constitute a valuable marker of cancer 
progression [12, 13]. Annexin A2 (ANXA2) in particular 
has been positively associated with malignant progression 
[14] and resistance to chemotherapy [15, 16]. ANXA2 
is unique among the annexins in that it possesses redox 
sensitive cysteine(s). Our laboratory has shown that 
extracellular ANXA2 binds to and reduces the enzyme 
plasmin and that ANXA2 oxidized during this reaction 
is subsequently reduced by the thioredoxin (Trx) redox 
system [17]. The presence of redox sensitive cysteine(s) 
on ANXA2 that can participate in cycles of oxidation 
and reduction, coupled with its ubiquitous and abundant 
expression in cells led us to hypothesize that this protein 
could play a role in cellular redox regulation. 
Here, we report a novel role for ANXA2 as a redox 
regulatory protein. We show that upon oxidative stress, 
ANXA2 depleted cells display higher levels of ROS, 
increased activation of the ROS-induced pro-apoptotic 
kinases: p38, JNK and Akt and higher sensitivity to 
oxidative stress-mediated cell death compared to control 
cells. We further identify the Cys8 residue as the redox 
sensitive cysteine of ANXA2 and show that this cysteine is 
reversibly oxidized by H2O2 and reduced by the thioredoxin 
redox system. In vivo studies show a significant increase in 
protein oxidation in the liver and lung tissues of ANXA2-
null mice compared to WT mice. Furthermore, the growth 
of tumors resulting from the subcutaneous injection of 
ANXA2-depleted human cancer cell lines, HT1080 
and A549, in mice showed severe growth impairment 
compared to control cells. Intraperitoneal injection of 
the antioxidant, N-acetyl cysteine (NAC) enabled these 
tumors to grow at a similar rate as the control tumors. We 
also observed enhanced protein oxidation in the ANXA2 
depleted HT1080 tumors compared to control tumors, 
which was prevented by NAC treatment. These results 
show that replacement of ANXA2 by another antioxidant, 
such as NAC, reverses the tumor growth deficit phenotype 
observed in the ANXA2 depleted cells, indicating that 
ANXA2 is a redox regulatory protein that plays a key role 
in tumorigenesis. Ex-vivo human cancer studies showed 
that in general, cancer cells express significantly higher 
levels of the reduced form of ANXA2 compared to normal 
tissue and that the up-regulation of the levels of reduced 
ANXA2 correlate with protection from oxidation of the 
proteins in these tumors, indicating that ANXA2 may 
function as a redox regulatory protein in human tumors.
RESULTS
ANXA2 protein is a redox sensor
In order to test if ANXA2 plays a role in cellular 
redox regulation we investigated if this protein is 
sensitive to H2O2-induced  oxidative  stress.  We  first 
examined ANXA2 sensitivity to a physiological stimulus 
that produced small localized increases in intracellular 
H2O2. The interaction of epidermal growth factor (EGF) 
with its receptor stimulates the activity of the NADPH 
oxidase, Nox resulting in a rapid and transient increase 
in intracellular H2O2 levels to nanomolar concentrations 
[18]. In order to determine if ANXA2 was oxidized by 
EGF-generated H2O2 we took advantage of the selective 
reactivity of Biotin-conjugated iodoacetamide (BIAM) 
with the reactive thiols of proteins. BIAM has been 
commonly used to quantify redox sensitive cysteine 
oxidation by ROS since it selectively reacts with redox 
sensitive cysteine(s) (Cys-S-) at physiological pH, but not 
with Cys-SH or oxidized cysteine residues (Cys-SOH 
or Cys-S-S-Cys) [19, 20]. A decrease in BIAM labeling 
of proteins, as monitored by streptavidin blot analysis, Oncotarget 2011; 2:  1075 - 1093 1077 www.impactjournals.com/oncotarget
indicates oxidation of the redox sensitive cysteine(s) by 
ROS. Accordingly, TIME cells were incubated with EGF 
and cellular extracts were either analyzed by SDS-PAGE 
followed by western blotting for ANXA2 or incubated 
with BIAM and the labeled/ biotinylated proteins purified 
by incubation with streptavidin beads, followed by SDS-
PAGE and western blotting for ANXA2. Our results 
showed that ANXA2 was highly oxidized by 30 minutes 
after EGF stimulation. However, by 1 hour after treatment, 
we observed an up-regulation in the levels of reduced 
ANXA2. Pre-incubation of cells with the antioxidant 
agent N-acetyl cysteine (NAC) prevented the EGF-
dependent oxidation of ANXA2 (Figure 1A), confirming 
that the EGF-dependent loss in the labeling of ANXA2 by 
BIAM was due to oxidation of ANXA2.
Next, we induced a slight increase in intracellular 
H2O2 levels by adding 200 μM H2O2 to the medium of 
TIME cells (see Figure 2A, grey bar), and observed that 
ANXA2 was transiently and reversibly oxidized by H2O2 
(Figure 1B). Three hours after treatment with H2O2, the 
levels of reduced ANXA2 were similar to untreated cells. 
Importantly, the total levels of ANXA2 were unchanged 
during the time course of the experiment. This result 
suggested that ANXA2 was oxidized by H2O2 and this 
oxidation occurred concomitantly with small changes of 
intracellular H2O2. We also examined the redox status of 
ANXA2 during more extreme oxidative stress conditions. 
We observed ANXA2 oxidation one hour after adding 
2 mM H2O2 to the medium of TIME cells. However, by 
Figure 1: Cellular ANXA2 is responsive to reactive oxygen species. (A) TIME cells were treated with 10 ng/ml EGF in the 
absence or presence of NAC for the times indicated; (B) TIME cells were treated with 200 μM H2O2 for the times indicated; (C) TIME 
cells were treated with 2 mM H2O2 for the times indicated; (D) TIME cells were treated with 5 mM H2O2 in the absence or presence of 10 
mM NAC for the times indicated; (E) TIME ANXA2 shRNA2 (KD) or TIME ANXA2 scramble cells were treated with 2 mM H2O2 for the 
times indicated. (A-E) Lysates were labeled with 10 μM BIAM and 200 µg of each labeled lysate was incubated with streptavidin beads. 
Total cell extracts and streptavidin purified samples (streptavidin PS) were subjected to SDS-PAGE followed by western blotting with the 
antibodies indicated. (F) 293T and MCF7 cells were treated with 100 μM H2O2 for two weeks. 20 μg of each cell lysate was subjected to 
SDS-PAGE followed by western blotting with the antibodies indicated.
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three hours, the levels of reduced ANXA2 were similar to 
untreated cells (Figure 1C). These results show that high 
levels of H2O2 can also result in the reversible oxidation 
of ANXA2. 
We investigated the redox status of ANXA2 under 
oxidative conditions that result in cell death. For these 
experiments, 5 mM H2O2 was added to the medium of 
TIME cells. The observed H2O2-dependent loss of BIAM 
labeling demonstrated that ANXA2 was oxidized by lethal 
concentrations of H2O2, however under these conditions, 
ANXA2 was irreversibly oxidized (Figure 1D). Pre-
incubation of cells with the antioxidant NAC prevented 
the oxidation of ANXA2 (Figure 1D), again confirming 
that oxidation of ANXA2 by H2O2 was responsible for the 
loss of BIAM reactivity.
Although our results suggested that ANXA2 was 
a target for oxidation by H2O2 it was unclear if ANXA2 
was involved in redox signaling or in redox regulation. 
Therefore, we generated stable ANXA2 knockdown 
cell lines using a retroviral vector-based shRNA system 
as  shown  in  Figures  1E  and  S1  and  confirmed  that 
other annexins were not down-regulated in the ANXA2 
depleted cells by western blot analysis (Figure S1). Next 
we increased intracellular H2O2 by addition of 2 mM H2O2 
to the medium of ANXA2 depleted TIME and control 
cells. The cell extracts were incubated with BIAM and the 
BIAM-labeled proteins were collected by incubation with 
streptavidin beads, followed by SDS-PAGE and western 
blot analysis. We examined the redox status of two well 
described redox-sensitive proteins, namely JunD, a major 
oxidative stress responsive transcription factor and actin 
which is also highly sensitive to changes in intracellular 
ROS levels. As shown in Figure 1E, oxidation of both 
JunD and actin was more rapid and pronounced in ANXA2 
depleted TIME cells compared to control cells suggesting 
that the intracellular levels of ROS were increased in 
ANXA2 depleted cells during oxidative stress. This result 
Figure 2: ANXA2 depleted cells accumulate higher levels of ROS upon oxidative stress. (A) TIME ANXA2 shRNA 2 or 
TIME ANXA2 scramble cells, (B) MCF7 ANXA2 shRNA 2 or MCF7 ANXA2 scramble cells and (C) LLC ANXA2 shRNA 3 or LLC 
ANXA2 scramble cells were incubated with 50 µM DCF-DA reagent. Cells were treated with different concentrations of H2O2 in the 
absence or presence of 10 mM NAC. Fluorescence was measured using a fluorometer plate reader. Data are represented as ± StDev (N=4).
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suggested that ANXA2 might regulate ROS levels during 
oxidative stress i.e. play a role in cellular redox regulation.
Several reports have shown that cells up-regulate 
antioxidant proteins in response to oxidative stress in 
order to maintain redox equilibrium and avoid cellular 
damage/death [21]. We investigated ANXA2 expression 
in response to a long term treatment with sub-lethal 
doses of H2O2. For this experiment we used cell lines that 
express ANXA2 at low levels, 293T cells, or moderate 
levels, MCF7 cells. These results showed up-regulation 
of ANXA2 expression in both cell lines under oxidative 
stress conditions, further supporting a role for ANXA2 as 
a redox regulatory protein (Figure 1F).
ANXA2 depleted cells accumulate higher levels of 
ROS upon oxidative stress
Since our results suggested that ANXA2 might 
regulate ROS levels during oxidative stress we 
measured intracellular ROS levels using the probe, 2’,7’ 
dichlorodihydrofluorescein diacetate (DCF-DA) in either 
Figure 3: ANXA2 depleted cells are more sensitive to oxidative stress induced death. (A) TIME ANXA2 shRNA2 or TIME 
ANXA2 scramble cells, (B) MCF7 ANXA2 shRNA2 or MCF7 ANXA2 scramble cells and (C) LLC ANXA2 shRNA 3 or LLC ANXA2 
scramble cells were treated with different concentrations of H2O2 in the absence (left panel) or presence of 10 mM NAC (middle panel) 
for 24 hours or treated with etoposide (right panel) for 48 hours. Cell viability was measured using the CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay. Average 490 nm absorbance for non-treated (NT) cells was set as 100% viability. (D) Ec50 values for 
the cells treated with H2O2 in the absence or presence of NAC as indicated. (E) Ec50 values for the cells treated with etoposide. Data was 
analysed using the two tailed Student’s t test and represented as ± StDev (N=4).
Figure 3
10mM3 .3mM 1.1mM 370µM 123µMN T
0
25
50
75
100
125
150 ANXA2 shRNA 3
ANXA2 scramble
P
e
r
c
e
n
t
a
g
e
 
o
f
 
l
i
v
e
 
c
e
l
l
s
Etoposide
750µM380µM 188µM9 4µM2 3µM1 2µMN T
0
10
20
30
40
50
60
70
80
90
100
110 ANXA2 shRNA 3
ANXA2 scramble
P
e
r
c
e
n
t
a
g
e
 
o
f
 
l
i
v
e
 
c
e
l
l
s
10mM3 .3mM 1.1mM3 70µM1 23µMN T
0
25
50
75
100
125
150 ANXA2 shRNA 3
ANXA2 scramble
P
e
r
c
e
n
t
a
g
e
 
o
f
 
l
i
v
e
 
c
e
l
l
s
C
LLC
1.5mM
*** ***
**
H2O2
*** ***
NS
NS
NS NS
NS
NS
NS NS
H2O2 + NAC
*
**
**
***
***
***
***
A
Etoposide
1.5mM 500µM 167µM5 5.5µM 18.5µM NT
0
10
20
30
40
50
60
70
80
90
100
110 ANXA2 shRNA 2
ANXA2 scramble
P
e
r
c
e
n
t
a
g
e
 
o
f
 
l
i
v
e
 
c
e
l
l
s
0.99mM0 .66mM0 .44mM0 .29mMN T
0
25
50
75
100
125
150 ANXA2 shRNA 2
ANXA2 scramble
P
e
r
c
e
n
t
a
g
e
 
o
f
 
l
i
v
e
 
c
e
l
l
s
0.99mM0 .66mM0 .44mM0 .29mMN T
0
20
40
60
80
100
120
140
160
180 ANXA2 shRNA 2
ANXA2 scramble
P
e
r
c
e
n
t
a
g
e
 
o
f
 
l
i
v
e
 
c
e
l
l
s
TIME
***
H2O2
NS
NS
NS NS
NS
NS
NS
NS
***
***
**
**
**
**
**
H2O2 + NAC
B
Etoposide
MCF7
H2O2 H2O2 + NAC
1.5mM5 00µM 170µM6 0µM2 0µMN T
0
25
50
75
100
125
150
175 ANXA2 shRNA 2
ANXA2 scramble
P
e
r
c
e
n
t
a
g
e
 
o
f
 
l
i
v
e
 
c
e
l
l
s
**
**
**
*
*
NS
4 mM 2 mM 1 mM 0.5 mM 0.25 mM
0
25
50
75
100
125
150
NS
NT
NS *
***
***
**
ANXA2 shRNA 2
ANXA2 scramble
P
e
r
c
e
n
t
a
g
e
 
o
f
 
l
i
v
e
 
c
e
l
l
s
4 mM 2 mM 1 mM 0
0
25
50
75
100
125
150
0.5 mM 0.25 mM
**
***
NS
NS NS NS
P
e
r
c
e
n
t
a
g
e
 
o
f
 
l
i
v
e
 
c
e
l
l
s
ANXA2 shRNA 2
ANXA2 scramble
DE
0
2
4
6
8
10
12
14
16
18
20
- -- - - - ++ ++ ++ NAC
MCF7 LLC TIME
ANXA2 shRNA
ANXA2 scramble
A
v
e
r
a
g
e
 
E
C
5
0
 
(
H
2
0
2
 
m
M
)
***
NS
***
*** NS
NS
H2O2 Etoposide
TIME MCF7 LLC
0.0
0.2
0.4
0.6
0.8
1.0
ANXA2 shRNA
ANXA2 scramble
A
v
e
r
a
g
e
 
E
C
5
0
 
(
E
t
o
p
o
s
i
d
e
 
m
M
)
***
***
***Oncotarget 2011; 2:  1075 - 1093 1080 www.impactjournals.com/oncotarget
untreated or H2O2 treated cells. We noted that depletion 
of ANXA2 did not seem to significantly affect the basal 
levels of ROS in normal (TIME) or cancer cells (MCF7 
and LLC) (Figure 2A-C). Strikingly, we observed that 
ROS levels were significantly higher in ANXA2 depleted 
cells after exposure to H2O2. Pre-incubation of cells with 
NAC blocked H2O2-induced increase in intracellular ROS, 
as expected. The levels of other redox regulatory proteins, 
including catalase, glutathione peroxidase, SOD-1, SOD-
2, peroxiredoxins (I-IV) and thioredoxin were not altered 
in the ANXA2 depleted cells or in cells over-expressing 
ANXA2 as examined by western blotting (Figure S2). We 
also did not detect increases in the levels of glutathione 
(data not shown). Together these results demonstrate 
that ANXA2 plays a role in the regulation of ROS levels 
during oxidative stress. 
ANXA2 protects cells from oxidative stress 
induced death
When oxidative stress exceeds the capacity of the 
cellular ROS scavenging system, cells succumb to the 
cytotoxic effects of the accumulated ROS and die [22, 23]. 
Since we observed increased levels of ROS in ANXA2 
depleted versus control cells following oxidative stress, 
we hypothesized that ANXA2 might play a role protecting 
cells from ROS induced cell death. In order to investigate 
this possibility we analyzed the viability of ANXA2 
depleted and control cells upon treatment with different 
concentrations of H2O2. We observed that cells depleted 
of ANXA2 were significantly more susceptible to H2O2-
induced death compared to control cells (Figure 3A-C, 
left panels). The concentration of H2O2 that resulted in 
50% loss in cell viability (EC50), decreased significantly in 
Figure 4: ANXA2 depleted cells show enhanced activation of oxidative stress responsive signaling proteins. (A, B) MCF7 
ANXA2 shRNA1, MCF7 ANXA2 shRNA2 or MCF7 ANXA2 scramble cells were treated with (A) 1 mM H2O2 for the times indicated or 
(B) 1 mM H2O2 in the absence or presence of 10 mM NAC for 30 min; (C) A549 ANXA2 shRNA2 or A549 ANXA2 scramble cells were 
treated with 1 mM H2O2 in the absence or presence of 10 mM NAC for the times indicated; (D) LLC ANXA2 shRNA3 or LLC ANXA2 
scramble cells were treated with 1 mM H2O2 for 30 minutes. (A-D) 25 µg of each cell lysate was subjected to SDS-PAGE followed by 
western blotting with the antibodies indicated.
Figure 4
AB
CD
ANXA2 shRNA1 ANXA2 scramble ANXA2 shRNA2
1 mM H2O2
NAC + -- +
- + - +
+ -- +
- + - +
+ -- +
- + - +
MCF7
P-JNK
JNK
ANXA2
P-Akt
Akt
tubulin
0 15’ 30’ 1h 01 h0 15’ 30’ 1h 01 h
NAC + --- -+ + --- -+
A549
ANXA2 shRNA2 ANXA2 scramble
ANXA2
P-p38
p38
P-JNK
JNK
P-Akt
Akt
tubulin
1 mM H2O2
0 10’ 30’ 1h 0 10’ 30’ 1h 0 10’ 30’ 1h
ANXA2 shRNA1 ANXA2 scramble ANXA2 shRNA2
ANXA2
P-p38
p38
P-JNK
JNK
P-Akt
Akt
actin
MCF7
1 mM H2O2
0 30’ 0 30’
ANXA2 
shRNA3
ANXA2 
scramble
LLC
ANXA2
P-p38
p38
P-JNK
JNK
P-Akt
Akt
actin
1 mM H2O2Oncotarget 2011; 2:  1075 - 1093 1081 www.impactjournals.com/oncotarget
ANXA2 depleted cells compared to control cells (Figure 
3D and table S1). Incubation of cells with NAC prior 
to treatment with H2O2 reversed this effect, as expected 
(Figure 3A-C, middle panels).
Many chemotherapeutic agents kill cancer cells 
through mechanisms that involve production of ROS. We 
observed that depletion of ANXA2 resulted in a significant 
increase in susceptibility to cell death induced by the ROS 
producing chemotherapeutic agent, etoposide (Figure 3A-
C, right panels) [24]. The EC50 values were significantly 
lower in ANXA2 depleted cells compared to control cells 
(Figure 3E and table S1). We also observed a significant 
decrease in the EC50 values for ANXA2 depleted TIME and 
LLC cells treated with the chemotherapeutic doxorubicin 
and ANXA2 depleted MCF7 cells treated with tamoxifen 
(Figure S3 and Table S1).
ANXA2 depleted cells show enhanced activation 
of oxidative stress responsive signaling proteins
After observing that ANXA2 depletion resulted in 
increased levels of ROS and loss of cell viability during 
oxidative stress, we investigated which oxidative stress 
responsive pathways were sensitive to the increased ROS 
levels observed in ANXA2 depleted cells. Cells typically 
use two main signaling pathways to respond to oxidative 
stress; the MAPK pathway that includes activation of the 
pro-apoptotic stress kinases c-Jun N-terminal kinases 
(JNKs) and p38 and the PI3K pathway, where activation 
of Akt by oxidative stress has been shown to be associated 
with apoptosis [25, 26]. 
We treated ANXA2 depleted and control cells 
with H2O2 and subjected the cell extracts to SDS-
PAGE followed by western blot analysis. The levels 
of phospho-p38 (P-p38), phospho-JNK (P-JNK) and 
Figure 5: Cys8 residue of cellular ANXA2 is a redox sensitive cysteine. (A) 293T cells were transiently transfected with pcDNA3 
empty vector (lane 1), pcDNA3-ANXA2 WT (lane 2), or a series of ANXA2 cysteine mutant plasmids: pcDNA3-ANXA2-Cys-8-Ala (lane 
3), pcDNA3-ANXA2-Cys-8-Ser (lane 4), pcDNA3-ANXA2-Cys-132-Ala (lane 5) or pcDNA3-ANXA2-Cys-132-Ser (lane 6) for 48 hours. 
20 μg of each cell extract was labeled with 20 μM BIAM and subjected to SDS-PAGE followed by western blotting with a streptavidin 
probe and the antibodies indicated. (B) 200 μg of each cell lysate was incubated with 20 μM BIAM, labeled proteins were purified with 
streptavidin beads. Cell extracts and streptavidin purified samples (streptavidin PS) were subjected to SDS-PAGE followed by western 
blotting for ANXA2. (C) TIME ANXA2 shRNA2 or TIME ANXA2 scramble cells were treated with 5 mM H2O2 in the absence or presence 
of 10 mM NAC for the times indicated. CA stands for competition assay; these samples were treated with 5 mM DTT prior to incubation 
with BIAM. Cell extracts were labeled with 10 μM BIAM, subjected to SDS-PAGE followed by western blotting with the antibodies 
indicated. (D) 0.65 μM of human recombinant ANXA2 or ANXA2C8S protein was incubated with the indicated concentrations of H2O2 for 
30 minutes, after what 10 μg/ml of catalase was added. Samples were labeled with 20 µM BIAM and subjected to SDS-PAGE followed by 
western blotting with a streptavidin probe and ANXA2 antibody. Protein band quantification was done using the Licor Odyssey software. 
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phospho-Akt (P-Akt) prior to oxidative insult were similar 
in ANXA2 depleted and control cells, indicating that these 
pathways were not being activated simply by depletion 
of ANXA2. Interestingly, upon oxidative stress ANXA2 
depleted cells showed significantly higher levels of P-p38, 
P-Akt and slightly elevated P-JNK compared to control 
cells (Figure 4), consistent with increased intracellular 
ROS levels and susceptibility of these cells to oxidative 
stress induced death. As predicted, pre-incubation of cells 
with NAC prevented the phosphorylation of these redox-
responsive kinases, confirming that their activation was 
due to oxidative stress (Figure 4B, C).
H2O2 oxidized ANXA2 is reversibly reduced by 
the Trx system
Collectively, our data indicated that ANXA2 
acted as a cellular redox regulatory protein; however 
the mechanism by which ANXA2 interacted with ROS 
was unclear. Therefore, we investigated which cysteine 
residue(s) of cellular ANXA2 were oxidized by ROS. 
Previous  work  from  our  laboratory  has  identified 
two cysteine residues of ANXA2, Cys8 and Cys132, as 
potential reactive residues based on their modification by 
glutathione in vitro. In order to further investigate which 
of these residues are redox sensitive cysteine(s) in vivo, 
we over-expressed ANXA2 wild-type (WT), and several 
cysteine mutants in 293T cells. These cells were chosen 
because they have low levels of endogenous ANXA2. 
The levels of over-expression of ANXA2 in the 293T 
cells were comparable to the endogenous levels of this 
protein in A549 breast cancer cells (Figure S4A) and 
lower than in the TIME cells (data not shown), indicating 
that ANXA2 over-expression in the 293T cells resulted in 
intracellular levels of ANXA2 were similar to the levels 
of ANXA2 observed in other cell lines. We incubated 
cell lysates from the 293T cells with BIAM, followed 
by SDS-PAGE and western blotting with a streptavidin 
probe, in order to identify BIAM labeled proteins. We 
observed that both ANXA2C8S and ANXA2C8A proteins 
were expressed in the 293T cells at comparable levels to 
ANXA2 WT, ANXA2C132S and ANXA2C132A. However, the 
ANXA2 Cys8 mutant proteins were not labeled by BIAM. 
In contrast, the labeling of ANXA2C132S and ANXA2C132A 
was similar to that of ANXA2 WT (Figure 5A). This result 
shows that only Cys8 and not Cys132 of ANXA2 is a redox 
sensitive cysteine in vivo. Furthermore, we also observed 
that ANXA2 was one of the main BIAM labeled bands in 
the whole cell extracts, indicating that the Cys8 residue of 
ANXA2 is highly reactive/ sensitive to oxidation. Next, 
we repeated this experiment, but collected the BIAM 
labeled proteins with streptavidin beads and performed 
a western blotting for ANXA2. As shown in Figure 5B 
we were unable to detect the ANXA2 Cys8 mutants. This 
established that Cys8 of ANXA2 is the redox sensitive 
cysteine.
In order to determine the relative abundance of 
ANXA2 compared with other redox sensitive proteins, 
we labeled the cell extracts of ANXA2 depleted and 
control TIME cells with BIAM, followed by SDS-PAGE 
and western blotting with a streptavidin probe (Figure 
5C). We did not detect a BIAM labeled band around 
36 KDa (ANXA2 molecular weight) in the ANXA2 
depleted TIME cells, and ANXA2 was one of the major 
proteins that reacted with BIAM in the TIME control 
cells, indicating the abundance of ANXA2 and the high 
reactivity of its Cys8 redox sensitive cysteine in these cells. 
Furthermore, we observed that oxidative stress resulted in 
a more dramatic and rapid oxidation of cellular proteins 
in the ANXA2 depleted TIME cells compared to control 
cells (Figure 5C), further suggesting that ANXA2 plays 
a role in redox regulation. Pre-incubation of cells with 
NAC prevented the oxidation of ANXA2 (Figure 5C, lane 
11). As an additional control we observed that addition of 
5 mM DTT to the cell extracts prior to incubation with 
BIAM abolished BIAM labeling of ANXA2. Since DTT 
competes with ANXA2 for the BIAM reagent, this result 
establishes that ANXA2 biotinylation is due to BIAM 
labeling of its redox sensitive cysteine and that ANXA2 
does not exist as a biotinylated protein in the cells (Figure 
5C, lane 12).
The reagent 3-(N-Maleimidylpropionyl)biocytin 
(NEM-biotin), although distinct in chemical reactivity 
from BIAM is also commonly used to identify redox 
sensitive cysteines in proteins [27]. We observed in 
experiments in which cell extracts were labeled with 
NEM-biotin that ANXA2 with C8S and C8A substitutions 
completely failed to react with this probe, while ANXA2 
with C132S and C132A substitutions reacted with this 
probe similarly to ANXA2 WT protein (Figure S4B). This 
result further supported that Cys8 residue is the only redox 
sensitive cysteine of ANXA2. 
H2O2 is a key ROS that also functions as a second 
messenger molecule in cells. To investigate whether the 
redox sensitive cysteine of ANXA2, Cys8, is a direct target 
for H2O2 oxidation, we incubated human recombinant 
ANXA2 with increasing amounts of H2O2, quenched 
the reaction with catalase and labeled the protein with 
BIAM followed by SDS-PAGE and western blotting 
with a streptavidin probe. These results showed that 
ANXA2 reacted with BIAM and that the BIAM labeling 
of ANXA2 decreased with increasing concentrations of 
H2O2 establishing that ANXA2 was oxidized by H2O2 
in a dose dependent manner (Figure 5D). However, the 
ANXA2C8S mutant protein did not react with the BIAM 
reagent as expected, confirming again that Cys8 residue is 
the redox sensitive cysteine of ANXA2 (Figure 5D).
The NADPH-dependent thioredoxin and glutathione 
redox systems are the best characterized antioxidant 
systems that are utilized by the cells to reduce/restore Oncotarget 2011; 2:  1075 - 1093 1083 www.impactjournals.com/oncotarget
oxidized proteins. We observed that incubation of 
a cellular lysate with H2O2 caused the oxidation of 
ANXA2 and that the subsequent addition of NADPH to 
this cellular lysate reversed ANXA2 oxidation (Figure 
6A). This result shows that ANXA2 can be reversibly 
oxidized by H2O2 and reduced by an NADPH-dependent 
antioxidant system in the cells. We next investigated if the 
Trx antioxidant system was involved in the restoration of 
oxidized ANXA2 to its reduced form. Human recombinant 
ANXA2 was incubated in the presence or absence of H2O2 
and the sample was labeled with BIAM. As expected, 
incubation of ANXA2 with H2O2 resulted in the oxidation 
of ANXA2. Interestingly, if the oxidized ANXA2 was 
then incubated with thioredoxin, both ANXA2 and a 48 
KDa complex of ANXA2 and thioredoxin were observed 
by SDS-PAGE and western blotting under non-reducing 
conditions. Furthermore, the formation of the ANXA2-
thioredoxin complex resulted in the reduction of H2O2-
oxidized ANXA2 (Figure 6B). As a control we repeated 
this experiment with ANXA1, an annexin closely related 
to ANXA2. ANXA1 does not possess a redox sensitive 
cysteine and the BIAM reagent did not label this protein. 
Since ANXA1 contains cysteine residues this result 
further supports the specific labeling of reactive thiols by 
BIAM (Figure 6B). We also observed that when human 
recombinant ANXA2 was incubated with 100 μM H2O2 
and NADPH (control), the ANXA2 was rapidly oxidized 
by 50% within one minute and by 90% after 30 minutes 
of incubation with H2O2. However, the inclusion of Trx 
reductase, Trx and NADPH (the Trx antioxidant system) 
resulted in the reduction of H2O2-oxidized ANXA2 
(Figure 6C). ANXA2 reduced form was similar to non 
treated protein until 5 minutes after addition of H2O2, at 
10 minutes post-incubation with H2O2 we observed a mild 
Figure 6: ANXA2 is a substrate of the Trx system. (A) TIME cell extracts were treated with the indicated amounts of H2O2, 
incubated with catalase after what mock or 500 μM of NADPH was added, as indicated.  Lysates were incubated with 10 μM BIAM and 
labeled proteins were purified with streptavidin beads. Cell extracts of non treated cells (lane 1) and streptavidin purified samples were 
subjected to SDS-PAGE followed by western blotting for ANXA2. (B) 2.5 μM ANXA2 or ANXA1 were incubated in the absence or 
presence of 100 μM H2O2 with or without 20 μM of Trx as indicated. Proteins were incubated in the absence or presence of 20 μM BIAM, 
subjected to SDS-PAGE under non-reducing conditions, followed by western blot analysis with the antibodies indicated. (C) 2 μM of 
human recombinant ANXA2 were incubated with 0.15 μM Trx reductase, 0.5 μM Trx, 500 μM NADPH (left panel) or with NADPH alone 
(right panel). 100 μM of H2O2 was added and samples were collected at the times indicated, after what 10 μg/ml of catalase was added. 
Samples were labeled with 20 μM BIAM and subjected to SDS-PAGE followed by western blotting with a streptavidin probe. (D) A549 
cells were either non-treated (NT) or treated with 1 mM H2O2 for 1 hour. Cells were lysed and immunoprecipitated with either IgG or anti-
ANXA2 antibodies as indicated (E) A549 cells were either non-treated (NT) or treated with 1 mM H2O2 for 1 hour. Cells were lysed and 
immunoprecipitated with IgG, anti-JunD or anti-Trx antibodies as indicated. (D-E) Immunoprecipitates and 20 µg of each cell extract were 
subjected to SDS-PAGE followed by western blotting with the antibodies indicated. Protein band quantification was done using the Licor 
Odyssey software.
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oxidation of ANXA2, around 30%, which increased by 
15 minutes post-incubation to 60%, but ANXA2 reduced 
levels were almost completely restored by 30 minutes 
after incubation with 100 μM H2O2 in the presence of 
the Trx redox system. Together these results indicate that 
H2O2-oxidized ANXA2 is reversibly reduced by the Trx 
system.
In order to determine if ANXA2 interacts with Trx in 
vivo we performed co-immunoprecipitation studies. Cells 
were incubated in the absence or presence of H2O2 and 
the cell lysates were immunoprecipitated with antibodies 
against ANXA2, Trx or JunD (control). These results 
confirmed that Trx and ANXA2 formed a complex whose 
levels increased 1.5 fold after stimulation with H2O2 
(Figure 6D, E). 
ANXA2-null mice show increased protein 
oxidation in the liver and lungs
We used ANXA2-null mice to study the role of 
ANXA2 in cellular redox regulation in vivo [28]. We 
reasoned that if ANXA2 played a role in cellular redox 
regulation its loss would result in enhanced oxidative 
stress which could be visualized by increased tissue 
protein oxidation. In order to investigate this possibility, 
we removed and homogenized organs from age-matched 
WT and ANXA2-null mice, labeled the cell extracts with 
BIAM, followed by SDS-PAGE and western blotting with 
a streptavidin probe. We observed a 50% decrease in the 
BIAM labeling of liver proteins in ANXA2-null mice 
compared to WT mice (Figure 7A) and a 30% decrease 
in BIAM labeling of lung proteins in ANXA2-null mice 
(Figure 7B). These data established that the liver and 
lung  tissues  of  ANXA2-null  mice  were  significantly 
more oxidized compared to WT mice. Interestingly, the 
oxidation status of spleen proteins was similar in the 
ANXA2-null and WT mice (Figure 7C).
ANXA2 redox regulatory function plays a role in 
tumorigenesis
Tumors are typically under higher oxidative stress 
compared to neighboring normal cells. We reasoned 
that if ANXA2 plays a role in cellular redox regulation 
its depletion will render cancer cells more susceptible 
to ROS induced damage/death during tumorigenesis. 
In order to investigate this hypothesis, we established 
ANXA2 depleted HT1080 and A549 cells and respective 
control cells and analyzed the early passaged cells 
for protein oxidation. As assessed by BIAM labeling, 
we observed no difference in the oxidation of cellular 
proteins in ANXA2 depleted versus control cell lines 
while cultured in optimal tissue culture conditions (Figure 
S5A, F). This was expected as these cells were not under 
oxidative stress. The ANXA2 depleted and control cells 
were injected subcutaneously into the right flank of NOD-
SCID mice and tumor growth was monitored by caliper 
measurement. We observed a significant impairment of 
tumor growth by ANXA2 depleted HT1080 and A549 
cancer cells compared to control cells (Figure 8A, B). At 
the experimental end point, the volume of tumors grown 
from ANXA2 depleted HT1080 cells was approximately 
85% smaller compared to tumors grown from control 
HT1080 cells. Furthermore, the volume of tumors grown 
from ANXA2 depleted A549 cancer cells was 70% smaller 
compared to A549 control tumors. The growth impairment 
of ANXA2 depleted A549 and HT1080 tumors was not 
due to decreased cell proliferation since we observed the 
Figure 7: ANXA2-null mice show increased protein 
oxidation in the liver and lungs. ANXA2 WT or ANXA2-
null mice age matched were sacrificed, (A) livers, (B) lungs and 
(C) spleens were removed, homogenized and labeled with 20 
µM BIAM. Samples were subjected to SDS-PAGE followed by 
western blotting with a streptavidin probe (left panels). The right 
panels show the quantification of the results on the left panels 
using the Licor Odyssey software. Data was analyzed using the 
two tailed Student’s t test and represented as ± StDev (N=7).
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same growth rate for ANXA2 depleted and control cell 
lines in culture (Figure S5E, H). In order to investigate if 
the growth impairment observed for the ANXA2 depleted 
tumors was due to ROS overload, we repeated the tumor 
growth experiments using ANXA2 depleted HT1080 and 
control cells and administered the antioxidant agent, NAC 
intraperitoneally every two days. These data showed that 
the growth rate of the ANXA2 depleted HT1080 tumors 
in mice receiving NAC injections was only slightly 
lower than the HT1080 control tumors (Figure 8C). At 
the end point of the experiment the ANXA2 depleted 
HT1080 tumor volume was only 8% smaller than the 
HT1080 control tumors. To investigate the redox status 
of the cellular proteins in the ANXA2 depleted HT1080 
Figure 8: ANXA2 redox regulatory function plays a role in tumorigenesis. (A) 2 X 106 HT1080 ANXA2 shRNA2 or HT1080 
ANXA2 scramble cells (N=10 per group) (B) 2 X 106 A549 ANXA2 shRNA2 or A549 ANXA2 scramble cells (N=8 per group) were 
injected subcutaneously into the right flank of NOD-SCID mice. (C) 2 X 106 HT1080 ANXA2 shRNA2 or HT1080 ANXA2 scramble 
cells were injected subcutaneously into the right flank of NOD-SCID mice treated with intraperitoneal injections of 150 mg/kg of NAC 
every two days (N=8 per group). (A-C) Tumor volume was measured for the time indicated using a caliper. Data was analyzed using the 
2-way Analysis of Variance (ANOVA) test and represented as ± SEM. (D-G) Three HT1080 ANXA2 shRNA2 and three HT1080 ANXA2 
scramble tumors from mice untreated (D) or treated (F) with NAC were homogenized, labeled with 20 μM BIAM, subjected to SDS-PAGE 
and analyzed by western blotting with a streptavidin probe. (E) and (G) Quantification of the results obtained in (D) and (F) using the Licor 
Odyssey software, respectively.
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or control tumors in the absence or presence of NAC 
injections, we removed HT1080 tumors from untreated or 
NAC treated mice and labeled the cellular extracts with 
BIAM. The tumors grown from ANXA2 depleted HT1080 
cells showed a 45% decrease in protein labeling (increased 
oxidation) compared to tumors grown from control 
HT1080 cells (Figure 8D, E). However, in mice receiving 
NAC injections, the labeling of tumor extracts by BIAM 
suggested similar levels of protein oxidation between 
tumors grown from ANXA2 depleted or control HT1080 
cells (Figure 8F, G). These results indicate that NAC 
prevented the intracellular protein oxidation observed in 
tumors grown from ANXA2 depleted HT1080 cells. We 
examined the redox status of protein extracts obtained 
from ANXA2 depleted HT1080 and control cells that 
were grown in culture for the time course of the animal 
experiments. Interestingly, we observed no difference in 
the levels of BIAM labeling between ANXA2 depleted 
Figure 9: ANXA2 redox status in human normal and tumor tissues. (A,B) Six different sets of human colon tissue extracts 
and one set of gastric tissue extracts, including normal tissue, outer tumor and core tumor were labeled with 20 μM BIAM; (A) Labeled 
extracts were purified by incubation with streptavidin beads. Cell extracts and streptavidin purified samples (strep PS) were subjected to 
SDS-PAGE followed by western blot analysis with the antibodies indicated; (B) 20 µg of each labeled cell extract were subjected to SDS-
PAGE, followed by western blotting with a streptavidin probe and the antibodies indicated. (C) H2O2 oxidizes Cys8 of ANXA2 resulting in 
the conversion of H2O2 to H2O. Oxidized ANXA2 is then reduced by the Trx redox system and can participate in further redox cycles. Thus 
a single molecule of ANXA2 can degrade several molecules of H2O2. 
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HT1080 and control cells that were grown in tissue 
culture conditions, under no oxidative stress, for three 
weeks (Figure S5B). This suggested that the oxidative 
stress that is known to occur during tumor growth, had a 
more severe effect on the ANXA2 depleted HT1080 cells 
than the control HT1080 cells. Collectively, these results 
support a role for ANXA2 in cancer cell redox regulation 
during tumorigenesis.
ANXA2 redox status in human tumors
We also investigated the redox status of ANXA2 in 
colon and gastric tumors compared to adjacent normal 
tissue. We examined six different human colon sample 
sets and one gastric set, including: normal tissue, outer 
tumor and core tumor. Cell extracts were labeled with 
BIAM and purified with streptavidin beads as described 
previously. We observed that the total levels of ANXA2 
were unchanged in all colon samples and moderately 
elevated in the gastric tumor. However, the levels of the 
reduced form of ANXA2 were up-regulated in the gastric 
tumor and in four out of the six colon tumors compared to 
normal tissues (Figure 9A). Furthermore, in the two sets 
of colon samples where this did not occur, we observed 
significant oxidation of total proteins in the tumors (Figure 
9 B- colon 1, 4). Colon 1 showed significantly elevated 
oxidation of total proteins in the outer and core tumors 
consistent with the high level of ANXA2 oxidation in these 
samples, whereas in colon 4 where the levels of reduced 
ANXA2 were similar in normal and tumor samples we 
only observed a significant oxidation of total proteins in 
the core/hypoxic tumor, which is under higher oxidative 
stress due to lack of blood supply.
DISCUSSION
In the current study we identify ANXA2 as a novel 
cellular redox regulatory protein that plays a significant 
role in cells undergoing oxidative stress and in particular 
during tumorigenesis. 
With  this  work  we  show  for  the  first  time  that 
Cys8 residue of ANXA2 is a redox sensitive cysteine 
that is reversibly oxidized by H2O2 and reduced by the 
thioredoxin system. Our results allow us to propose the 
following mechanistic model: H2O2 reacts with the Cys8 
of ANXA2 resulting in the oxidation of this residue and 
the conversion of H2O2 to H2O. Oxidized ANXA2 is then 
reduced by the Trx redox system and can participate in 
further redox cycles (Figure 9C). Thus a single molecule 
of ANXA2 can degrade several molecules of H2O2.
Considering the abundance and wide distribution of 
ANXA2 in cells and the fact that ANXA2 contains a highly 
reactive cysteine residue that is a direct target of H2O2, we 
hypothesized that ANXA2 might play an important role 
in the cellular response to oxidative stress, particularly 
H2O2-mediated stress. As mentioned before, H2O2 is a 
main second messenger in cell signaling transduction and 
is induced by a number of signaling pathways that regulate 
cell proliferation, survival and apoptosis. A tight control in 
the levels of cellular H2O2 is then very important for cell 
signaling regulation and in order to avoid protein, lipid 
and DNA oxidative damage. Here we show that ANXA2 
depleted cells exhibit significantly enhanced levels of ROS 
and increased oxidation of redox sensitive proteins upon 
H2O2 treatment compared to control cells. Although we 
did not observe differences in the basal levels of ROS in 
untreated ANXA2 depleted versus control cells using the 
DCF-DA reagent, it is possible that the DCF-DA reagent 
is not sensitive enough to detect small differences in the 
basal concentrations of cellular H2O2 using a fluorometer 
plate reader. Alternatively, it is possible that ANXA2 only 
plays a significant redox regulatory role under oxidative 
stress conditions, while under physiological conditions 
other antioxidant proteins are able to compensate for the 
loss of ANXA2.
The enhanced ROS levels observed in the ANXA2 
depleted cells upon oxidative stress resulted in increased 
sensitivity of these cells to ROS induced cell death 
compared to control cells. Chemotherapeutic agents that 
induce oxidative stress are thought to selectively kill 
cancer cells because the elevation of ROS caused by these 
agents is less toxic to normal cells that have lower levels 
of endogenous ROS. However, we surprisingly found that 
our non cancer cell model was more sensitive to oxidative 
stress compared to cancer cells. Nevertheless, these are 
different cell types and for this reason it is not appropriate 
to directly compare their sensitivity to ROS induced death. 
Furthermore, redox adaptation by cancer cells can in some 
cases make these cells more resistant to ROS induced 
death. For instance it has been shown that the MCF10 
normal breast cells are more sensitive to H2O2 induced 
cell death compared to MCF7 breast cancer cells, because 
MCF7 cells up-regulate the peroxidases, peroxiredoxin 
I and II in order to counteract the elevation of ROS and 
prevent cellular damage/death [29]. Interestingly, we 
observed that ANXA2 protein levels increased by two-
fold after treatment of 293T and MCF7 cells with 100 μM 
H2O2 for two weeks. This result suggests that cells might 
respond to elevations in ROS levels/ oxidative stress by 
inducing the expression of the redox regulatory protein, 
ANXA2.
The observed increased sensitivity of ANXA2 
depleted cells to death induced by chemotherapeutics 
that up-regulate ROS led us to postulate that blocking the 
expression of ANXA2 in cancer cells might constitute a 
potential therapeutic strategy. Several reports have shown 
that up-regulation of ANXA2 in tumors correlates with 
chemoresistance, but they were unable to explain the 
mechanism(s) by which this occurs. Our results provide an 
explanation for this observation, since ANXA2 antioxidant Oncotarget 2011; 2:  1075 - 1093 1088 www.impactjournals.com/oncotarget
function will protect the cancer cells from oxidative 
damage/death induced by the chemotherapeutics. 
We also analyzed the activation of H2O2 responsive 
signaling pathways in the ANXA2 depleted versus 
control cells. The major intracellular sensor of oxidative 
stress induced by H2O2 is the apoptosis signal-regulated 
kinase-1 (ASK-1). ASK-1 directly activates MKK3/
MKK6 and MKK4/MKK7 kinases which phosphorylate 
the pro-apoptotic kinases, p38 and JNK [30, 31, 32]. 
Therefore, the phosphorylation status of p38 and JNK 
provides a sensitive readout of the redox status of the 
cell. Elevated levels of H2O2 also lead to activation of the 
PI3K pathway kinase, Akt through inactivation of PTEN 
phosphatase [33]. Although Akt signaling is usually 
associated with cell survival, recently it has been shown 
that under oxidative stress conditions Akt further increases 
the intracellular levels of ROS through an increase in 
oxygen consumption and inhibition of FoxO transcription 
factors sensitizing cells to ROS-mediated apoptosis [26]. 
We observed enhanced activation of the pro-apoptotic 
kinases p38, JNK and Akt in ANXA2 depleted cancer 
cells treated with H2O2 compared to control cells. These 
results provide a molecular mechanism that explains the 
increased sensitivity of these cells to ROS induced death.
If ANXA2 functions as a redox regulatory protein 
then it is reasonable to expect that the ANXA2-null mice 
would exhibit a phenotype. However, the cellular redox 
system  is  complex  with  significant  cross  talk  between 
various proteins and often several proteins compensate 
for each others function in a relatively efficient way under 
non pathological conditions. Considering the importance 
of cellular redox regulation it is not surprising that cells 
possess redox proteins with overlapping functions. For 
instance, homozygous catalase-null mice, which are 
completely  deficient  in  catalase  expression,  the  major 
cellular enzyme that decomposes H2O2, develop normally 
and show no gross abnormalities under physiological 
conditions. In fact, mice deficient in catalase were not 
more vulnerable to hyperoxia-induced lung injury; nor 
did their eye lenses showed any increased susceptibility 
to oxidative stress generated by a photochemical 
reaction,suggesting that the antioxidant function of 
catalase in these two models of oxidative injury is either 
negligible, which is unlikely, or is compensated by other 
cellular antioxidant protein(s) [34]. The only phenotype 
observed in these knockout mice was a retarded rate of 
breakdown of H2O2 by liver, lung and lens tissue slices 
compared to the wild-type mice.
Our animal studies showed that ANXA2-null mice 
have enhanced liver and lung protein oxidation compared 
to WT mice. Liver cells have a high metabolic rate since 
this organ is involved in protein, lipid and carbohydrate 
metabolism, synthesis of urea and the manufacture 
of bile, resulting in increased ROS production by the 
mitochondria. The lung is constantly exposed to oxidative 
stress due to gas exchange between the alveoli and the red 
blood cells. It is not surprising that depletion of the redox 
regulatory protein, ANXA2 in these organs will lead to 
increased oxidative stress. We did not observe significant 
differences in spleen protein oxidation between ANXA2-
null and WT mice. This could be due to the fact that most 
splenocytes show a rapid turnover and are unlikely to 
accumulate as much ROS induced protein damage as the 
long-lived liver or lung cells.
During tumorigenesis, cancer cells typically exhibit 
increased ROS generation. In order to balance the 
proliferative advantages of ROS up-regulation versus its 
potential risks due to protein, lipid and DNA damage, 
cancer cells induce the over-expression and/or activation 
of antioxidant/redox regulatory proteins. Our in vivo tumor 
studies showed that tumor growth in animals injected with 
either ANXA2 depleted HT1080 or ANXA2 depleted 
A549 cancer cells was severely impaired compared to 
tumor growth in animals injected with control HT1080 
and A549 cancer cells, respectively. In order to investigate 
if the growth impairment of ANXA2 depleted tumors was 
specifically  due  to  ANXA2  redox  regulatory  function 
we treated mice possessing ANXA2 depleted HT1080 
tumors, with the antioxidant NAC. We observed that in 
the presence of NAC tumor growth in animals injected 
with ANXA2-depleted cancer cells was identical to tumor 
growth in animals injected with control cancer cells. These 
results show that replacement of ANXA2 by another 
antioxidant reagent, such as NAC, reversed the growth 
impairment phenotype observed for the ANXA2 depleted 
tumors. It is then reasonable to propose that ANXA2 
depletion from the cancer cells resulted in a loss of 
cellular redox regulatory capability which became critical 
as these cancer cells grew into tumors and were subjected 
to oxidative stress in the tumor site. The loss of ANXA2-
dependent redox regulation during tumor growth was 
restored by the antioxidant activity of NAC. Consistent 
with this rationale was the observation that in the absence 
of NAC, the HT1080 ANXA2 depleted tumors showed 
significantly  enhanced  protein  oxidation  (sensor  for 
cellular oxidative damage) compared to control tumors, 
while there was no enhanced protein oxidation in the 
ANXA2 depleted tumors grown in mice that received the 
antioxidant NAC. Taking these data together we therefore 
propose that ANXA2 plays a major role in tumorigenesis 
by functioning as a redox regulatory protein. 
It was interesting to observe that NAC by itself 
stimulated tumor growth of the control cancer cells. This 
result is consistent with the reports that compared to 
normal cells, cancer cells are under significant oxidative 
stress and that agents that increase cellular ROS levels can 
selectively kill cancer cells [35, 36]. In this situation NAC 
can act by lowering the levels of H2O2 in the HT1080 
tumors, thus increasing cell proliferation or decreasing 
cell death. This result also indicates that oxidative stress Oncotarget 2011; 2:  1075 - 1093 1089 www.impactjournals.com/oncotarget
plays a major role and is a limiting step in tumor growth 
under our experimental conditions. 
Although controversial, ANXA2 has also been 
implicated in other cellular processes, in particular 
plasmin activation, which could also contribute to cancer 
progression [37]. Several studies have shown that plasmin 
activation does not play a major role in the subcutaneous 
growth of primary tumors. It has been shown that sub-
cutaneous inoculation of plasminogen negative tumour 
cells (LLC) in plasminogen-null mice produced tumors 
only 10-35% smaller compared to control mice [38], 
while we observed a 70-85% decrease in tumor volume in 
the A549 and HT1080 ANXA2 depleted tumors compared 
to control tumors. Another study showed that both WT 
and plasminogen-null mice carrying the Polyoma middle 
T antigen under the control of the mouse mammary tumor 
virus long terminal repeat uniformly developed multiple 
bilateral mammary tumors that were indistinguishable 
[39]. More importantly, plasmin generation by ANXA2 
or other plasminogen receptors is not regulated by NAC, 
but is dependent on the presentation of a C-terminal 
lysine residue by the plasminogen receptor [40, 17, 
37]. Consequently, if the growth deficit observed in the 
ANXA2 depleted tumors was due to decreased plasmin 
activation, the addition of NAC would not reverse the 
phenotype and restore the growth of ANXA2 depleted 
tumors as observed.
Finally, our ex-vivo experiments using human colon 
and  gastric  samples  showed  that  five  out  of  the  seven 
sets of samples analyzed exhibited up-regulation of the 
reduced form of ANXA2 in the tumors compared to 
normal tissue. Whereas the two tumor samples where we 
did not observe up-regulation of reduced ANXA2 showed 
increased total protein oxidation. These results show that 
ANXA2 antioxidant function is important in maintaining 
redox equilibrium in the human tumors, since in general 
tumors show elevated levels of reduced ANXA2 and loss 
of reduced ANXA2 in tumors led to increased protein 
oxidation/oxidative stress. 
In this study, we show that although ANXA2-
null mice do not have an overt phenotype under non-
pathological conditions, ANXA2 plays an important role 
during disease, namely supporting cancer progression by 
acting as a redox regulatory protein. Our observations that 
liver and lung tissue proteins from ANXA2-null mice are 
more oxidized compared to WT mice and that the proteins 
extracted from tumors produced by ANXA2-depleted 
cancer cells are more oxidized than proteins extracted 
from tumors produced by control cancer cells are also 
consistent with our proposed function for ANXA2 as an 
antioxidant. 
Several reports have shown that up-regulation 
of ANXA2 levels is positively associated with cancer 
progression and chemoresistance, nevertheless the 
function of ANXA2 during these processes remained 
unknown.  This  is  the  first  report  that  elucidates  a 
molecular mechanism by which ANXA2 contributes to 
tumorigenesis and resistance to chemotherapy, by acting 
as a redox regulatory protein. Development of strategies 
that are aimed at preferentially killing cancer cells 
through mechanisms that cause additional ROS overload 
are currently being used. Agents that block ANXA2 
expression could therefore be useful to preferentially kill 
malignant cells.
MATERIALS AND METHODS
Cell Culture, transfections and cell lines
MCF-7, A549, HT1080, LLC and 293T cell lines 
were obtained from ATCC and maintained in Dulbecco’s 
modified  Eagle’s  medium  (Invitrogen)  supplemented 
with 10% fetal bovine serum (FBS) and 100 U/ml of 
penicillin/streptomycin, in a humidified incubator in an 
atmosphere of 5% CO2 at 37ºC. TIME endothelial cells 
were obtained from Dr McMahon [41] and maintained 
in EGM2 medium (Lonza) supplemented with 10% FBS 
and 100U/ml of penicillin/streptomycin, in a humidified 
incubator in an atmosphere of 5% CO2 at 37ºC. ANXA2 
depleted cell lines were obtained by transfection of 
Phoenix packaging cells with 4 µg of the pSUPER-retro 
plasmids described below using 12 µl of the lipofectamine 
2000 transfection reagent according to the manufacturers’ 
instructions. 48 hours after transfection the target cells 
were infected with Phoenix supernatants and selected with 
2 µg/ml of puromicin. 293T cells in 6 well plates (60-70% 
confluency) were transiently transfected for 48 hours with 
1 μg of either pcDNA3 (empty vector control), pcDNA3-
ANXA2, pcDNA3-ANXA2-Cys-8-Ala, pcDNA3-
ANXA2-Cys-8-Ser, pcDNA3-ANXA2-Cys-132-Ala 
or pcDNA3-ANXA2-Cys-132-Ser plasmids described 
below using 3 µl of the lipofectamine 2000 transfection 
reagent according to the manufacturers’ instructions.
Plasmids
pSUPER-retro-ANXA2 shRNA1 was constructed 
by cloning the dsDNA oligo 5’-GAT CCC CCC TGG TTC 
AGT GCA TTC AGT TCA AGA GAC TGA ATG CAC 
TGA ACC AGG TTT TTA-3’ and 5’-AGC TTA AAA 
ACC TGG TTC AGT GCA TTC AGT CTC TTG AAC 
TGA ATG CAC TGA ACC AGG GGG-3’ into pSUPER.
retro.puro (OligoEngine), pSUPER-retro-ANXA2 
shRNA2 was constructed by cloning the dsDNA oligo 
5’-GAT CCC CGT GCA TAT GGG TCT GTC AAT TCA 
AGA GAT TGA CAG ACC CAT ATG CAC TTT TTA-3’ 
and 5’-AGC TTA AAA AGT GCA TAT GGG TCT GTC 
AAT CTC TTG AAT TGA CAG ACC CAT ATG CAC 
GGG-3’ into pSUPER.retro.puro (OligoEngine) and the 
pSUPER-retro-ANXA2 scramble was constructed by Oncotarget 2011; 2:  1075 - 1093 1090 www.impactjournals.com/oncotarget
cloning the dsDNA oligo 5’-GAT CCC CGT GCA TAT 
GGG TCT GTC CAT TAG AGA GAT TGA CAG ACC 
CAT ATG CAC TTT TTA-3’ and 5’-AGC TTA AAA AGT 
GCA TAT GGG TCT GTC AAT CTC TCT AAT GGA 
CAG ACC CAT ATG CAC GGG-3’ into pSUPER.retro.
puro (OligoEngine). pSUPER-retro-ANXA2 shRNA3 
(Murine) was constructed by cloning the dsDNA oligo 
into pSUPER.retro.puro (OligoEngine) and pSUPER-
retro-ANXA2  shRNA2  (Human  specific)  was  used  as 
ANXA2 scramble (Murine). pcDNA3-ANXA2 plasmid 
was constructed by PCR amplification of ANXA2 cDNA 
and cloning it into the pcDNA3 vector. The primers used 
for PCR amplification were the following: 5’-AAG CTT 
GGA TCC GCC GCC ACC ATG TCT ACT-3’ and 5’-
GAT CGC GGC CGC TCA GTC ATC TCC ACC AC-3’. 
pcDNA3-ANXA2-Cys-8-Ala was constructed by point 
mutation of the ANXA2 gene in the pcDNA3-ANXA2 
vector using the QuikChange II Site-directed mutagenesis 
kit (Agilent Technologies). The primers used to introduce 
the point mutation in the ANXA2 gene were the following: 
5’-CT GTT CAC GAA ATC CTG GCA AAG CTC AGC 
TTG GAG GG-3’ and 5’-CC CTC CAA GCT GAG 
CTT TGC CAG GAT TTC GTG AAC AG-3’. pcDNA3-
ANXA2-Cys-8-Ser was constructed by point mutation of 
the ANXA2 gene in the pcDNA3-ANXA2 vector using 
the QuikChange II Site-directed mutagenesis kit (Agilent 
Technologies). The primers used to introduce the point 
mutation in the ANXA2 gene were the following: 5’-GTT 
CAC GAA ATC CTG AGC AAG CTC AGC TTG GAG 
GG-3’ and 5’-CC CTC CAA GCT GAG CTT GCT CAG 
GAT TTC GTG AAC-3’. pcDNA3-ANXA2-Cys-132-Ala 
was constructed by point mutation of the ANXA2 gene 
in the pcDNA3-ANXA2 vector using the QuikChange 
II Site-directed mutagenesis kit (Agilent Technologies). 
The primers used to introduce the point mutation in the 
ANXA2 gene were the following: 5’-CTC ATT GAG 
ATC ATC GCT TCC AGA ACC AAC CAG GAG CTG-3’ 
and 5’- CAG CTC CTG GTT GGT TCT GGA AGC GAT 
GAT CTC AAT GAG-3’. pcDNA3-ANXA2-Cys-132-Ser 
was constructed by point mutation of the ANXA2 gene 
in the pcDNA3-ANXA2 vector using the QuikChange 
II Site-directed mutagenesis kit (Agilent Technologies). 
The primers used to introduce the point mutation in the 
ANXA2 gene were the following: 5’-CTC ATT GAG 
ATC ATC AGC TCC AGA ACC AAC CAG GAG CTG-3’ 
and 5’- CAG CTC CTG GTT GGT TCT GGA GCT GAT 
GAT CTC AAT GAG-3’. 
Antibodies
The following antibodies were used for western blot 
analysis: ANXA2 antibody: 610069 (BD Transduction 
laboratories), S100A10 antibody: 610071 (BD 
Transduction laboratories), ANXA1 antibody: sc-12740 
(Santa Cruz Biotechnology - SCBT), ANXA4 antibody: 
sc-1930 (SCBT), ANXA5 antibody: sc-8300 (SCBT), 
ANXA6 antibody: sc-11388 (SCBT), SOD-1 antibody: 
sc-11407 (SCBT), SOD-2 antibody: sc-30080 (SCBT), 
PRDX I antibody: sc-7381, PRDX II antibody: sc-
33572, PRDX I-IV antibody: sc-33574 (SCBT), catalase 
antibody: ab1877-10 (AbCam), GPX 1/2 antibody: sc-
133160, Trx antibody: sc-20146 (SCBT), phospho-JNK 
antibody: 9251S (Cell Signaling), JNK antibody: 9252 
(Cell Signaling), phospho-p38 antibody: 9211S (Cell 
Signaling), p38 antibody: 9212 (Cell Signaling), phospho-
Akt antibody: 9271S (Cell Signaling), Akt antibody: 
9272 (Cell Signaling), actin antibody (AC-40): A3853 
(SIGMA), β-tubulin antibody (H-235): sc-9104 (SCBT), 
JunD antibody: sc-44 (SCBT). 
Immunoprecipitation assays
For Trx, JunD and ANXA2 co-immunoprecipitations, 
cells were washed two times with PBS, lysed with 
Triton X-100 lysis buffer (50 mM Tris pH 7.4, 0.15% 
Triton X-100, 150 mM NaCl, 1.5 mM EGTA, protease 
inhibitors, 1 mM NaVO4, 10 mM NaF- degassed) for 10 
minutes on ice. Cell lysates were pre-cleared for 1 h with 
protein G-Sepharose, incubated with specific antibodies 
for 1 h and then with 50% slurry of protein G-Sepharose 
for 1 h. Beads were washed five times with 500 μl of lysis 
buffer, resuspended with 25 μl 2X SDS-PAGE loading 
buffer, boiled for 5 minutes, subjected to SDS-PAGE and 
analysed by western blotting. The following antibodies 
were used for immunoprecipitation studies: ANXA2: 
D1/274.5 mouse monoclonal (made in house), JunD: sc-
44 (SCBT) and Trx: sc-20146 (SCBT).
Western blot analysis
For western blot analysis 20 μg of cell lysates, unless 
noted, were subjected to SDS-PAGE, transferred onto a 
nitrocellulose membrane, incubated with appropriate 
antibodies and visualized using a Licor Odyssey scanner 
(Li-cor Biosciences). Quantification of protein bands was 
done using the Licor Odyssey scanner software.
Determination of redox sensitive cysteine 
oxidation
Redox sensitive cysteine oxidation was determined 
using  the  thiol-specific  biotinylation  reagent,  BIAM 
(SIGMA). For experiments that utilized cultured cells, 
after mock, EGF or H2O2 treatment, cells were washed 
two times with PBS and scraped with BIAM lysis buffer 
(10 µM BIAM, 50 mM Tris pH 7.4, 0.2% Triton X-100, 
200  mM  NaCl,  2  mM  EGTA,  1  mM  EDTA,  5  μg/ml 
catalase, protease inhibitors, 1 mM NaVO4, 10 mM NaF-
degassed). The resultant lysates were incubated for 20 
minutes at 37oC, after which 2 mM iodoacetamide (IA) Oncotarget 2011; 2:  1075 - 1093 1091 www.impactjournals.com/oncotarget
was added to block any further protein labeling. In other 
experiments, lysates were prepared by homogenization 
of tissues or tumor samples with lysis buffer (50 mM 
Tris pH 7.4, 0.2% Triton X-100, 200 mM NaCl, 2 mM 
EGTA, 1 mM EDTA, protease inhibitors, 1 mM NaVO4, 
10 mM NaF-degassed) followed by incubation at 4ºC for 
15 minutes and centrifugation at 20000 g for 20 minutes 
at 4ºC. The lysates were incubated with 20 µM BIAM 
for 20 minutes at 37oC followed by addition of 2 mM IA. 
In order to isolate BIAM-labeled proteins, cell extracts 
that had been labeled with BIAM were incubated with 
50 μl of streptavidin Dynabeads (Invitrogen) for 1 hour 
at 4oC with rotation. Streptavidin beads were washed 3 
times with 500 μl of lysis buffer, resuspended with 25 μl 
of 2X SDS-PAGE loading buffer and subjected to SDS-
PAGE followed by western blotting. All human samples 
were obtained with patients’ informed consent and the 
work was approved by the Capital Health Research Ethics 
Board.
NADPH assay
250  μg  of  TIME  cell  lysates  were  either  non-
treated or treated with H2O2 for 15 minutes. Lysates were 
incubated with 100 μg/ml of catalase for 10 minutes at 
37oC, after which 500 μM of NADPH was added to the 
samples and incubated for 30 minutes at 37oC. Samples 
were incubated with 10μM BIAM reagent and labeled 
proteins  were  purified  by  incubation  with  streptavidin 
beads. Cell extracts and BIAM labeled purified samples 
were subjected to SDS-PAGE and analyzed by western 
blotting.
Trx assay
2.5 μM of either ANXA2 or ANXA1 were either non 
treated or treated with 100 μM of H2O2 in the presence or 
absence of 20 μM Trx for 15 minutes at 37ºC. Samples 
were labeled with 20 μM BIAM for 20 minutes at 37oC, 
subjected to SDS-PAGE under non reducing conditions 
and analyzed by western blotting.
Intracellular ROS measurement
The fluorescent dye DCF-DA (Invitrogen) was used 
to measure the levels of ROS in cells. 2 X 104 cells/well 
were seeded in 96 wells plate and incubated overnight at 
37oC. Cell medium was removed and replaced with 1% 
FBS  medium  containing  50  µM  DCF-DA.  Cells  were 
incubated for 30 minutes at 37oC, washed with PBS and 
complete medium was added. Cells were treated with H2O2 
± NAC, incubated for 1 hour at 37oC and fluorescence was 
measured (Excitation: 488 nm, Emission: 535 nm) using a 
fluorometer plate reader.
Cell viability assay
Cell viability was determined by using the CellTiter 
96® AQueous Non-Radioactive Cell Proliferation Assay 
(Promega) according to the manufacturer’s instructions.
Tumor development in NOD-SCID mice
NOD-SCID mice were injected subcutaneously into 
the right flank with 2 X 106 HT1080 ANXA2 shRNA 2, 
HT1080 ANXA2 scramble, A549 ANXA2 shRNA2 or 
A549 ANXA2 scramble cells in 100 µl of PBS in the 
absence or presence of 150 mg/kg of NAC administered 
intraperitoneally every two days. Tumor volume was 
measured every two/three days by caliper measurement 
and  volume  calculated  by  the  formula  (V=0.5  X  L  X 
W2). At the experimental endpoint mice were euthanized 
by CO2 inhalation, the ANXA2 depleted HT1080 and 
control tumors were removed and protein lysates were 
prepared. Tumors were homogenized with 1ml lysis 
buffer (50 mM Tris pH 7.4, 0.2 % Triton-X100, 200 mM 
NaCl, 1 mM EDTA, 2 mM EGTA, 1 mM NaVO4, 10 mM 
NaF and protease inhibitors-degassed). Homogenates 
were centrifuged at 20000 g for 20 minutes at 4ºC and 
supernatants were stored. All mouse experiments were 
performed in accordance with protocols approved by the 
University Committee on Laboratory Animals (UCLA) at 
Dalhousie University, Halifax, N.S., Canada.
Statistical analysis
The  statistical  significance  of  the  difference  in 
cytotoxicity,  DCF  quantification  and  protein  oxidation 
was evaluated using two tailed Student’s t test. The 
statistical difference in tumor growth between the ANXA2 
depleted HT1080 versus control cells with or without 
NAC and ANXA2 depleted A549 versus control cells was 
analyzed using the 2-way Analysis of Variance (ANOVA) 
test. These data analyses were performed using the Prism 
software (GraphPad, San Diego, CA). In every case a P 
value of less than 0.05 (*), less than 0.01(**) and 0.001 
(***) was considered statistically significant. 
Inventory of Supplemental data
Supplemental data includes supplemental methods, 
five figures and one table.
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